• Alda 1: From ALDH2 Activation to Translation

  2026-10-03

  A source-grounded perspective on how Alda 1 can help translational researchers investigate aldehyde biology, cardioprotection, cardiomyocyte proliferation, and radiation injury while keeping preclinical evidence distinct from clinical promise.

• GDC-0941: PI3K Inhibition Workflow

  2026-10-02

  GDC-0941 provides a practical way to connect PI3K/Akt pathway inhibition with proliferation, apoptosis, resistance, and epithelial-to-mesenchymal transition assays. This workflow combines product-specific dosing benchmarks with insights from recent pancreatic cancer research while clearly separating validated evidence from hypothesis-generating combinations.

• Cepharanthine: From Models to Meaning

  2026-10-01

  Cepharanthine is a biscoclaurine alkaloid whose activity can be interpreted across stromal cells, patient-derived organoids, and animal lesions. This article presents an evidence-calibrated framework for connecting apoptosis, DNA damage, and translational assay decisions without overstating therapeutic readiness.

• LncRNA Gm16410 in PM2.5-Induced EndMT

  2026-10-01

  This study links chronic PM2.5 exposure to pulmonary EndMT through the TGF-β1/Smad3/p-Smad3 axis and identifies lncRNA Gm16410 as a regulatory candidate. Its combined mouse, cell, transcriptomic, and functional approach provides a framework for studying how environmental particles may promote pulmonary fibrosis.

• DNMT3B, Nanaomycin A, and NEPC Plasticity

  2026-09-30

  Therapy-induced lineage plasticity is reshaping how researchers think about treatment-resistant prostate cancer. New evidence positions DNMT3B as a mechanistic link between enzalutamide resistance, neuroendocrine differentiation, and stemness, while (S,S)-Nanaomycin A provides a practical pharmacologic tool for testing that biology.

• GSH-Responsive MOF Nanoparticles for Melanoma Therapy

  2026-09-30

  Hao and colleagues developed ICG-MOF-SS-AUNP12, a zirconium-based metal-organic framework that combines near-infrared photothermal therapy with GSH-responsive PD-1/PD-L1 blockade. The study provides a preclinical design strategy for coupling tumor ablation with dendritic-cell maturation and antitumor immune activation.

• Berberine, Tuft Cells, and Estrogen-Deficiency Bone Loss

  2026-09-29

  A recent Phytomedicine study identifies a gut–bone mechanism in which berberine increases intestinal butyrate, activates GPR41-associated tuft-cell expansion, restores barrier function, and improves the Th17/Treg balance in estrogen-deficient rodents. Its combination of ovariectomy models, microbiome profiling, transcriptomics, immune analysis, knockout mice, and intestinal organoids provides a useful framework for testing gut-mediated osteoimmune effects.

• Cyclo (-RGDfC) for High-Throughput Integrin Assays

  2026-09-29

  Cyclo (-RGDfC) combines cyclic RGD recognition with a practical workflow for αvβ3-focused adhesion, migration, angiogenesis, and tumor-targeting studies. Pairing this peptide with 96-well hydrogel printing adds spatial control, plate-scale reproducibility, and a path toward patterned cell assays.

• Tamoxifen in Bone Research: Tool or Confounder?

  2026-09-28

  Tamoxifen is a selective estrogen receptor modulator and a widely used CreER trigger, but its biology can complicate studies of skeletal progenitors. This article connects Tamoxifen use to research on Gli1+ cells in glucocorticoid-induced osteoporosis and outlines controls for interpreting bone phenotypes.

• Oligo (dT) 25 Beads for Endometrial Cancer RNA

  2026-09-27

  Connect NSD1–PPARγ–PTEN biology to practical transcript analysis with selective eukaryotic mRNA capture. This workflow guide explains how to use magnetic beads for RT-qPCR or sequencing, while clarifying what mRNA purification can—and cannot—reveal about protein methylation and glycolysis.

• Interpreting Cancer Drug Responses In Vitro

  2026-09-26

  Hannah R. Schwartz’s dissertation distinguishes relative viability, which combines growth inhibition and cell loss, from fractional viability, which focuses on drug-induced killing. This distinction supports more informative assay design and prevents cytostatic and cytotoxic responses from being treated as equivalent.

• Mitochondrial Permeability Transition Pore Assay Kit

  2026-09-26

  Connect mitochondrial pore opening to apoptosis with a Calcein AM fluorescent probe and cobalt-quenching workflow. This guide translates hepatocyte findings in Treponema pallidum research into practical assay controls, optimization steps, and interpretation safeguards.

• Z-VAD-FMK in Cell-Death Pathway Discrimination

  2026-09-25

  Z-VAD-FMK is a cell-permeable pan-caspase inhibitor used to test caspase-dependent apoptosis. This article connects its practical role to research on oxidative-stress-induced ferroptosis in tendon stem cells—and explains what inhibitor rescue can, and cannot, establish about cell-death mechanisms.

• InstaBlue Protein Stain Solution: Gel Workflow

  2026-09-25

  InstaBlue Protein Stain Solution provides a rapid Coomassie-based option for visualizing protein bands in polyacrylamide gels without fixation or destaining. It can support gel checks and selection of bands for downstream work, but it is not a substitute for a validated protein quantification assay or a method for identifying proteins.

• L-NMMA Acetate: A Causal Probe of NO Signaling

  2026-09-24

  L-NMMA acetate helps researchers test whether nitric oxide signaling contributes to a biological effect—not simply whether it changes alongside that effect. This article applies that causal framework to dental follicle cell osteogenesis and outlines the controls needed to interpret NOS inhibition responsibly.

429 records 1/29 page Next 12345 下5页 Last page